. The KSHV DNA viral load was undetectable in 22% of the studied cases or was detectable at low levels in KS patients, whereas it was always detectable in the MCD and PEL patients. The three KSHVassociated diseases were associated with significantly different levels of KSHV DNA in whole blood (P Ͻ 0.0001) ( Fig. 1) . The KSHV DNA rates were the highest in the samples from the MCD patients (median, 3.94 log 10 copies/10 6 cells [range, 1.00 to 7.00]), followed by the PEL patients (3.46 log 10 copies/10 6 cells [2.23 to 4.83]) and, finally, the KS patients (1.92 log 10 copies/10 6 cells [1.00 to 5.60]). In patients with KS and MCD, KSHV DNA levels and CD4 cell counts were negatively correlated (for KS patients, r s ϭ Ϫ0.25, P ϭ 0.02; for MCD patients, r s ϭ Ϫ0.43, P ϭ 0.02), confirming the role of immunosuppression in KSHV disease development (5) . Among the PEL patients, KSHV DNA levels were approximately 100 to 1,000 times higher in total effusion fluid samples than in blood samples, which is in agreement with the physiopathology of the disease but is also linked to the high number of KSHV copies per lymphoma cell (2) . KSHV DNA levels in whole-blood samples from patients with MCD were significantly higher than in those from patients with KS (P Ͻ 0.0001), in contrast to the levels in plasma samples reported by Haq et al. (7) . We know that KSHV remains mostly latent in KS and PEL cases, whereas KSHV is found in the lytic cycle in about 15% of MCD cases (2) . Moreover, latent and replicating viral KSHV DNA is present in cells (9) . Thus, analyses of plasma samples might underestimate KSHV DNA levels in the peripheral blood compartment in comparison to whole-blood samples, especially in patients with MCD.
Our study results reinforce the concept that KSHV DNA biomarkers would be helpful to guide diagnosis of and manage KSHV-associated diseases. Even if used for KS diagnosis, KSHV DNA quantification should be interpreted with caution (about a quarter of quantification assays indicate that KSHV DNA levels are undetectable); increases in levels in blood would trigger KS disease progression or other underlying KSHV malignancies.
